Search

Your search keyword '"Garmo, Hans"' showing total 1,061 results
Start Over Author "Garmo, Hans"
1,061 results on '"Garmo, Hans"'

18. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial

Author

Baig, Umair, Aya, Haleema, Husnain Iqbal, Mohammed, Kum, Francesca, Bultitude, Matthew, Glass, Jonathan, Khan, Azhar, Makanjuola, Jonathan, McCabe, John E., Samsuddin, Azi, McIlhenny, Craig, Brewin, James, Kulkarni, Shashank, Khwaja, Sikandar, Islam, Waliul, Marsh, Howard, Bhat, Taher, Thomas, Benjamin, Cutress, Mark, Housami, Fadi, Nedas, Timothy, Bates, Timothy, Mukherjee, Rono, Graham, Stuart, Bordenave, Matthieu, Coker, Charles, Ahmed, Shwan, Symes, Andrew, Calvert, Robert, Lynch, Ciaran, Long, Ronan, Patterson, Jacob M., Rukin, Nicholas J., Khan, Shahid A., Dasgupta, Ranan, Brown, Stephen, Grey, Ben, Mahmalji, Waseem, Lam, Wayne, Scheitlin, Walter, Saelzler, Norbert, Fiedler, Marcel, Ishikawa, Shuhei, Sasaki, Yoshihiro, Sazawa, Ataru, Shinno, Yuichiro, Mochizuki, Tango, Peter Jessen, Jan, Steiner, Roland, Wendt-Nordahl, Gunnar, Atassi, Nabil, Kohns, Heiko, Cox, Ashley, Rendon, Ricardo, Lawen, Joseph, Bailly, Greg, Marsh, Trevor, Aydın, Abdullatif, Ahmed, Kamran, Abe, Takashige, Raison, Nicholas, Van Hemelrijck, Mieke, Garmo, Hans, Ahmed, Hashim U., Mukhtar, Furhan, Al-Jabir, Ahmed, Brunckhorst, Oliver, Shinohara, Nobuo, Zhu, Wei, Zeng, Guohua, Sfakianos, John P., Gupta, Mantu, Tewari, Ashutosh, Gözen, Ali Serdar, Rassweiler, Jens, Skolarikos, Andreas, Kunit, Thomas, Knoll, Thomas, Moltzahn, Felix, Thalmann, George N., Lantz Powers, Andrea G., Chew, Ben H., Sarica, Kemal, Shamim Khan, Muhammad, and Dasgupta, Prokar

Published
2022
Full Text
View/download PDF

21. Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.

Author

Holmberg, Lars, Skogmar, Sten, Garmo, Hans, Hagberg, Oskar, Häggström, Christel, Gårdmark, Truls, Ströck, Viveka, Aljabery, Firas, Jahnson, Staffan, Hosseini, Abolfazl, Jerlström, Tomas, Sherif, Amir, Söderkvist, Karin, Ullén, Anders, Malmström, Per‐Uno, and Liedberg, Fredrik

Subjects
BLADDER cancer, INTRAVESICAL administration, BCG immunotherapy, TRANSURETHRAL resection of bladder, NON-muscle invasive bladder cancer, DRUGS
Abstract

Objectives: To investigate the cumulative incidence proportion of disseminated or local Bacillus Calmette‐Guérin (BCG) infections after adjuvant BCG instillations in patients with non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods: We analysed the timing and occurrence of BCG infections and absolute and relative risk in relation to patient characteristics available in the Swedish nationwide database 'BladderBaSe 2.0'. The cumulative incidence proportion of a BCG infection was indicated by a reported diagnosis of tuberculosis (TB) in the patient registry or filing a prescription for tuberculostatic drugs. Results: The cumulative incidence proportion was 1.1% at the 5‐year follow‐up in 5033 patients exposed to adjuvant BCG instillations. The incidence rate was highest during the first 2 years after start of BCG instillations. Women had a lower risk than men (hazard ratio 0.23, 95% confidence interval 0.07–0.74). Age and calendar time at diagnosis, comorbidity, tumour risk group, previous medication with corticosteroids, immunosuppressive drugs, or time between transurethral resection of the bladder tumour and commencing the adjuvant BCG instillation were not associated with risk. Conclusions: These data further supports that the overall risk of a BCG infection after BCG‐instillation treatment for NMIBC is low. The great majority of infections occur in the first 2 years, calling for an awareness of the diverse symptoms of BCG infection during this period. We provide evidence for male sex as a risk factor; however, the statistical precision is low and with a risk of selection bias, making it difficult to rule out the other suggested risk factors without further studies with different approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Generic solution of the heterogeneity-induced competing risk problem in survival analysis

Author

van Baardewijk, Hans, Garmo, Hans, van Hemelrijck, Mieke, Holmberg, Lars, and Coolen, Anthony CC

Subjects
Statistics - Applications
Abstract

Most papers implicitly assume competing risks to be induced by residual cohort heterogeneity, i.e. heterogeneity that is not captured by the recorded covariates. Based on this observation we develop a generic statistical description of competing risks that unifies the main schools of thought. Assuming heterogeneity-induced competing risks is much weaker than assuming risk independence. However, we show that it still imposes sufficient constraints to solve the competing risk problem, and derive exact formulae for decontaminated primary risk hazard rates and cause-specific survival functions. The canonical description is in terms of a cohort's covariate-constrained functional distribution of individual hazard rates of all risks. Assuming proportional hazards at the level of individuals leads to a natural parametrisation of this distribution, from which Cox regression, frailty and random effects models, and latent class models can all be recovered in special limits, and which also generates parametrised cumulative incidence functions (the language of Fine and Gray). We demonstrate with synthetic data how the generic method can uncover and map a cohort's substructure, if such substructure exists, and remove heterogeneity-induced false protectivity and false exposure effects. Application to real survival data from the ULSAM study, with prostate cancer as the primary risk, is found to give plausible alternative explanations for previous counter-intuitive inferences., Comment: 41 pages, 7 figures

Published
2013

35. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study.

Author

Rask, Gunilla, Wadsten, Charlotta, Acs, Balazs, Hartman, Johan, Fredriksson, Irma, Garmo, Hans, Wärnberg, Fredrik, and Sund, Malin

Subjects
BREAST cancer, DUCTAL carcinoma, CARCINOMA in situ, EPIDERMAL growth factor receptors, METASTATIC breast cancer, TUMOR-infiltrating immune cells
Abstract

Background: Studies identifying risk factors for death from breast cancer after ductal carcinoma in situ (DCIS) are rare. In this retrospective nested case–control study, clinicopathological factors in women treated for DCIS and who died from breast cancer were compared with those of patients with DCIS who were free from metastatic disease. Methods: The study included patients registered with DCIS without invasive carcinoma in Sweden between 1992 and 2012. This cohort was linked to the National Cause of Death Registry. Of 6964 women with DCIS, 96 were registered with breast cancer as cause of death (cases). For each case, up to four controls (318; women with DCIS, alive and without metastatic breast cancer at the time of death of the corresponding case) were selected randomly by incidence density sampling. Whole slides of tumour tissue were evaluated for DCIS grade, comedo necrosis, and intensity of periductal lymphocytic infiltrate. Composition of the immune cell infiltrate, expression of oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and proliferation marker Ki-67 were scored on tissue microarrays. Clinical information was obtained from medical records. Information on date, site, and histological characteristics of local and distant recurrences was obtained from medical records for both cases and controls. Results: Tumour tissue was analysed from 65 cases and 195 controls. Intense periductal lymphocytic infiltrate around DCIS was associated with an increased risk of later dying from breast cancer (OR 2.21. 95% c.i. 1.01 to 4.84). Tumours with more intense lymphocytic infiltrate had a lower T cell/B cell ratio. None of the other biomarkers correlated with increased risk of breast cancer death. Conclusion: The immune response to DCIS may influence the risk of dying from breast cancer. Current management of ductal carcinoma in situ (DCIS) is unsatisfactory because low- and high-risk groups of DCIS cannot be defined accurately and reproducibly. This study is the first to show that the degree of tumour infiltrating lymphocytes in DCIS affects the risk of dying from breast cancer. This means that the degree and composition of the immune environment, needs to be consider in order to risk stratify DCIS accurately and personalize treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Angiosarcoma in the breast: a population-based cohort from Sweden

Author

Olander, Susanne, primary, Wennstig, Anna-Karin, additional, Garmo, Hans, additional, Holmberg, Lars, additional, Nilsson, Greger, additional, Blomqvist, Carl, additional, Karlsson, Fredrik, additional, Wickberg, Åsa, additional, Wärnberg, Fredrik, additional, Sund, Malin, additional, and Wadsten, Charlotta, additional

Published
2023
Full Text
View/download PDF

42. PD27-09 PATIENT REPORTED OUTCOMES AFTER RADICAL PROSTATECTOMY OR RADIOTHERAPY FOR PROSTATE CANCER, A REGISTER-BASED NATIONWIDE STUDY

Author

Bergengren, Oskar, primary, Corsini, Christian, additional, Carlsson, Stefan, additional, Franck-Lissbrant, Ingela, additional, Garmo, Hans, additional, Hjelm-Eriksson, Marie, additional, Fransson, Per, additional, Kindblom, Jon, additional, Robinson, David, additional, Westerberg, Marcus, additional, Stattin, Pär, additional, and Carlsson, Sigrid, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results